TY  - JOUR
AU  - Koschny, Ronald
AU  - Boehm, Christina
AU  - Sprick, Martin R
AU  - Haas, Tobias L
AU  - Holland, Heidrun
AU  - Xu, Li-Xin
AU  - Krupp, Wolfgang
AU  - Mueller, Wolf C
AU  - Bauer, Manfred
AU  - Koschny, Thomas
AU  - Keller, Marius
AU  - Sinn, Peter
AU  - Meixensberger, Juergen
AU  - Walczak, Henning
AU  - Ganten, Tom M
TI  - Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
JO  - Journal of neuropathology and experimental neurology
VL  - 73
IS  - 11
SN  - 1554-6578
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2017-03699
SP  - 1034 - 1046
PY  - 2014
AB  - A meningioma is the most common primary intracranial tumor in adults. Here, we investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in 37 meningiomas. Freshly isolated primary meningioma cells were treated with TRAIL with or without different sensitizing protocols, and apoptotic cell death was then quantified. Mechanisms of TRAIL sensitization were determined by a combination of Western blotting, flow cytometry, receptor complex immunoprecipitation, and siRNA-mediated knockdown experiments. Tumor necrosis factor-related apoptosis-inducing ligand receptor expression was analyzed using immunohistochemistry and quantified by an automated software-based algorithm. Primary tumor cells from 11 (29.7
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Boronic Acids (NLM Chemicals)
KW  - GRAMD4 protein, human (NLM Chemicals)
KW  - Mitochondrial Proteins (NLM Chemicals)
KW  - Pyrazines (NLM Chemicals)
KW  - TNF-Related Apoptosis-Inducing Ligand (NLM Chemicals)
KW  - TNFSF10 protein, human (NLM Chemicals)
KW  - Bortezomib (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25289891
DO  - DOI:10.1097/NEN.0000000000000129
UR  - https://inrepo02.dkfz.de/record/127676
ER  -